| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 28 | 2025 | 800 | 3.870 |
Why?
|
| Cognition Disorders | 19 | 2020 | 437 | 3.020 |
Why?
|
| Brain | 23 | 2025 | 707 | 2.950 |
Why?
|
| Dementia | 13 | 2019 | 236 | 2.410 |
Why?
|
| Cognitive Dysfunction | 8 | 2025 | 449 | 2.100 |
Why?
|
| Cognition | 14 | 2025 | 641 | 1.900 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2020 | 82 | 1.860 |
Why?
|
| Diabetes Mellitus | 3 | 2023 | 40 | 1.680 |
Why?
|
| Antibodies, Antiphospholipid | 3 | 2019 | 19 | 1.380 |
Why?
|
| Humans | 60 | 2025 | 12240 | 1.370 |
Why?
|
| Aged | 40 | 2025 | 4000 | 1.360 |
Why?
|
| Neuropsychological Tests | 24 | 2025 | 558 | 1.300 |
Why?
|
| Aged, 80 and over | 34 | 2025 | 2152 | 1.290 |
Why?
|
| Cardiovascular Diseases | 4 | 2025 | 166 | 1.260 |
Why?
|
| Aging | 14 | 2020 | 680 | 1.220 |
Why?
|
| Brain Infarction | 5 | 2021 | 36 | 1.200 |
Why?
|
| Female | 45 | 2025 | 6974 | 1.110 |
Why?
|
| Biomarkers | 5 | 2025 | 294 | 1.010 |
Why?
|
| Male | 43 | 2025 | 6815 | 1.010 |
Why?
|
| Memory Disorders | 4 | 2020 | 68 | 0.980 |
Why?
|
| Insulin | 3 | 2023 | 41 | 0.920 |
Why?
|
| Cerebral Infarction | 4 | 2023 | 63 | 0.910 |
Why?
|
| Insulin Resistance | 2 | 2023 | 19 | 0.910 |
Why?
|
| Neurofibrillary Tangles | 4 | 2018 | 64 | 0.890 |
Why?
|
| Plaque, Amyloid | 3 | 2018 | 45 | 0.830 |
Why?
|
| Metformin | 1 | 2023 | 9 | 0.800 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2024 | 36 | 0.790 |
Why?
|
| Neuroimaging | 4 | 2021 | 66 | 0.780 |
Why?
|
| Memory, Episodic | 1 | 2023 | 43 | 0.780 |
Why?
|
| Cerebral Amyloid Angiopathy | 6 | 2021 | 57 | 0.760 |
Why?
|
| tau Proteins | 6 | 2021 | 88 | 0.760 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 9 | 0.750 |
Why?
|
| Blood Pressure | 3 | 2019 | 99 | 0.730 |
Why?
|
| Neuropathology | 2 | 2019 | 42 | 0.680 |
Why?
|
| Risk Factors | 13 | 2024 | 1049 | 0.660 |
Why?
|
| Longitudinal Studies | 16 | 2020 | 651 | 0.650 |
Why?
|
| Cohort Studies | 11 | 2019 | 827 | 0.620 |
Why?
|
| Adipokines | 1 | 2019 | 5 | 0.600 |
Why?
|
| Cerebral Arteries | 3 | 2016 | 18 | 0.600 |
Why?
|
| Motor Disorders | 1 | 2019 | 13 | 0.580 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2019 | 20 | 0.580 |
Why?
|
| Depressive Disorder | 1 | 2019 | 90 | 0.550 |
Why?
|
| Apolipoprotein E4 | 5 | 2025 | 106 | 0.550 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 60 | 0.550 |
Why?
|
| Signal Transduction | 1 | 2019 | 246 | 0.540 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 726 | 0.530 |
Why?
|
| Hypertension | 1 | 2018 | 85 | 0.530 |
Why?
|
| Parkinsonian Disorders | 3 | 2007 | 91 | 0.510 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2021 | 29 | 0.390 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 12 | 0.370 |
Why?
|
| Movement Disorders | 1 | 2012 | 32 | 0.370 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 400 | 0.360 |
Why?
|
| Diabetes Complications | 2 | 2016 | 28 | 0.330 |
Why?
|
| Neurodegenerative Diseases | 2 | 2001 | 60 | 0.320 |
Why?
|
| Amyloid beta-Peptides | 2 | 2018 | 98 | 0.310 |
Why?
|
| Prospective Studies | 5 | 2018 | 817 | 0.300 |
Why?
|
| Heme Oxygenase-1 | 2 | 2009 | 3 | 0.300 |
Why?
|
| Middle Aged | 9 | 2024 | 4043 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 46 | 0.270 |
Why?
|
| Asparagine | 1 | 2006 | 2 | 0.250 |
Why?
|
| Lysine | 1 | 2006 | 3 | 0.250 |
Why?
|
| Independent Living | 2 | 2018 | 137 | 0.250 |
Why?
|
| Hospitalization | 2 | 2018 | 158 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 41 | 0.240 |
Why?
|
| Neuroglia | 2 | 2007 | 19 | 0.240 |
Why?
|
| Cholesterol | 2 | 2025 | 30 | 0.230 |
Why?
|
| Mutation | 1 | 2006 | 175 | 0.230 |
Why?
|
| Exercise | 2 | 2025 | 233 | 0.220 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 19 | 0.220 |
Why?
|
| Postmortem Changes | 3 | 2019 | 17 | 0.220 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2025 | 3 | 0.220 |
Why?
|
| Cellular Senescence | 1 | 2025 | 13 | 0.220 |
Why?
|
| Lysosomes | 1 | 2025 | 13 | 0.220 |
Why?
|
| Autopsy | 5 | 2021 | 174 | 0.220 |
Why?
|
| Mental Status Schedule | 3 | 2018 | 38 | 0.210 |
Why?
|
| Body Mass Index | 2 | 2020 | 221 | 0.210 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2024 | 19 | 0.200 |
Why?
|
| 5-Methylcytosine | 1 | 2023 | 2 | 0.190 |
Why?
|
| Memory | 2 | 2020 | 112 | 0.190 |
Why?
|
| Creatinine | 1 | 2002 | 29 | 0.180 |
Why?
|
| Age Factors | 3 | 2021 | 350 | 0.180 |
Why?
|
| DNA Methylation | 1 | 2023 | 93 | 0.180 |
Why?
|
| Anniversaries and Special Events | 1 | 2021 | 2 | 0.180 |
Why?
|
| Neuromuscular Diseases | 1 | 2001 | 2 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 464 | 0.170 |
Why?
|
| Incidence | 3 | 2018 | 338 | 0.170 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2021 | 7 | 0.170 |
Why?
|
| Genetic Variation | 2 | 2016 | 44 | 0.170 |
Why?
|
| Vascular Diseases | 1 | 2021 | 25 | 0.160 |
Why?
|
| Inflammation | 2 | 2022 | 124 | 0.150 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2019 | 9 | 0.150 |
Why?
|
| Arteriolosclerosis | 2 | 2018 | 25 | 0.150 |
Why?
|
| Comorbidity | 4 | 2014 | 209 | 0.150 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2019 | 9 | 0.150 |
Why?
|
| Memantine | 1 | 2019 | 5 | 0.150 |
Why?
|
| Leptin | 1 | 2019 | 11 | 0.150 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 8 | 0.150 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2019 | 14 | 0.150 |
Why?
|
| Frontal Lobe | 1 | 1999 | 32 | 0.140 |
Why?
|
| Temporal Lobe | 1 | 1999 | 29 | 0.140 |
Why?
|
| Proteomics | 1 | 2019 | 39 | 0.140 |
Why?
|
| Brain Diseases | 1 | 1999 | 30 | 0.140 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 66 | 0.140 |
Why?
|
| Central Nervous System Infections | 1 | 1998 | 4 | 0.140 |
Why?
|
| Economics | 1 | 2018 | 8 | 0.140 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1998 | 11 | 0.140 |
Why?
|
| Tuberculosis | 1 | 1998 | 12 | 0.140 |
Why?
|
| Community Health Planning | 1 | 2018 | 7 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2018 | 64 | 0.140 |
Why?
|
| Depression | 1 | 2020 | 229 | 0.130 |
Why?
|
| White Matter | 2 | 2016 | 52 | 0.130 |
Why?
|
| Health Literacy | 1 | 2018 | 45 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2017 | 36 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2017 | 186 | 0.120 |
Why?
|
| Arterioles | 1 | 2016 | 9 | 0.120 |
Why?
|
| Organ Specificity | 1 | 2016 | 18 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 1 | 2016 | 11 | 0.120 |
Why?
|
| Neoplasms | 1 | 2017 | 94 | 0.110 |
Why?
|
| Microglia | 1 | 2016 | 64 | 0.110 |
Why?
|
| Linear Models | 2 | 2016 | 115 | 0.110 |
Why?
|
| Motor Skills | 1 | 2015 | 32 | 0.110 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2014 | 6 | 0.110 |
Why?
|
| Phosphatidylserines | 1 | 2014 | 6 | 0.110 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2014 | 6 | 0.110 |
Why?
|
| Autoantigens | 1 | 2014 | 10 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2014 | 46 | 0.110 |
Why?
|
| Lewy Bodies | 2 | 2012 | 96 | 0.110 |
Why?
|
| Cerebral Cortex | 2 | 2006 | 77 | 0.100 |
Why?
|
| Motor Activity | 1 | 2015 | 175 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 423 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 171 | 0.090 |
Why?
|
| Chicago | 3 | 2020 | 453 | 0.090 |
Why?
|
| Adult | 4 | 2006 | 3557 | 0.090 |
Why?
|
| Research Design | 1 | 2012 | 79 | 0.090 |
Why?
|
| Microcirculation | 1 | 2011 | 15 | 0.080 |
Why?
|
| Amyloid | 1 | 2010 | 20 | 0.080 |
Why?
|
| Atrophy | 2 | 2001 | 29 | 0.080 |
Why?
|
| Lewy Body Disease | 2 | 2012 | 54 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2022 | 55 | 0.070 |
Why?
|
| Sterols | 1 | 2009 | 2 | 0.070 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2007 | 30 | 0.070 |
Why?
|
| Statistics as Topic | 2 | 2006 | 51 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2025 | 1478 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2006 | 295 | 0.070 |
Why?
|
| Housing for the Elderly | 1 | 2007 | 5 | 0.060 |
Why?
|
| Receptors, Erythropoietin | 1 | 2007 | 1 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2006 | 1 | 0.060 |
Why?
|
| Family Health | 1 | 2006 | 18 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2006 | 18 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 36 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 24 | 0.060 |
Why?
|
| Smoking | 1 | 2007 | 84 | 0.060 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2007 | 67 | 0.060 |
Why?
|
| Heart Failure | 1 | 2007 | 77 | 0.060 |
Why?
|
| Apolipoproteins E | 2 | 2022 | 100 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2021 | 105 | 0.060 |
Why?
|
| Cell Count | 1 | 2005 | 38 | 0.060 |
Why?
|
| Causality | 2 | 2020 | 22 | 0.060 |
Why?
|
| Logistic Models | 2 | 2015 | 196 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2025 | 170 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2017 | 115 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 153 | 0.050 |
Why?
|
| Phospholipases A2, Cytosolic | 1 | 2022 | 1 | 0.050 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2022 | 4 | 0.050 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2022 | 4 | 0.050 |
Why?
|
| Epoxide Hydrolases | 1 | 2022 | 7 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2002 | 10 | 0.050 |
Why?
|
| Disease Progression | 2 | 2016 | 290 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2002 | 27 | 0.050 |
Why?
|
| Mice | 1 | 2025 | 760 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 103 | 0.040 |
Why?
|
| Parkinson Disease | 2 | 2005 | 314 | 0.040 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2001 | 8 | 0.040 |
Why?
|
| Spinocerebellar Degenerations | 1 | 2001 | 1 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 2001 | 5 | 0.040 |
Why?
|
| Aphasia, Primary Progressive | 1 | 2001 | 2 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2001 | 28 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2021 | 6 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2001 | 151 | 0.040 |
Why?
|
| Genotype | 2 | 2015 | 169 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2001 | 96 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 156 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 128 | 0.040 |
Why?
|
| Calcium | 1 | 2022 | 288 | 0.040 |
Why?
|
| Life Style | 1 | 2020 | 102 | 0.040 |
Why?
|
| AIDS Dementia Complex | 1 | 2000 | 31 | 0.040 |
Why?
|
| Animals | 1 | 2025 | 2092 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2001 | 281 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 94 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 60 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1998 | 2 | 0.030 |
Why?
|
| Meningitis | 1 | 1998 | 2 | 0.030 |
Why?
|
| DNA Fingerprinting | 1 | 1998 | 4 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 1998 | 7 | 0.030 |
Why?
|
| Canada | 1 | 1998 | 21 | 0.030 |
Why?
|
| Species Specificity | 1 | 1998 | 28 | 0.030 |
Why?
|
| United States | 3 | 2006 | 989 | 0.030 |
Why?
|
| alpha-Synuclein | 1 | 2018 | 59 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 151 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2017 | 12 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 20 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2016 | 5 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 45 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 119 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 20 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 72 | 0.030 |
Why?
|
| Actigraphy | 1 | 2015 | 41 | 0.030 |
Why?
|
| Time Factors | 1 | 2016 | 695 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 14 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2009 | 5 | 0.020 |
Why?
|
| Neocortex | 1 | 2009 | 17 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2009 | 12 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 47 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 2009 | 19 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 64 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2009 | 89 | 0.020 |
Why?
|
| Neurons | 1 | 2009 | 164 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2007 | 24 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 23 | 0.020 |
Why?
|
| Bias | 1 | 2006 | 16 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 125 | 0.010 |
Why?
|
| Community Health Services | 1 | 2006 | 19 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 218 | 0.010 |
Why?
|
| Dementia, Vascular | 1 | 2005 | 19 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2005 | 49 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 116 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 68 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 15 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 2005 | 22 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 252 | 0.010 |
Why?
|
| Clergy | 1 | 2005 | 39 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 161 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 324 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2000 | 125 | 0.010 |
Why?
|